-

03:58:06 PM

LIVE Real Time TWST Stock Market News

TWST - Twist Bioscience Corp

04/22/21 8:00 AM

Nasdaq : TWST

Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 second quarter ended March 31, 2021, following the close

RHEA-AI

neutral

04/16/21 8:00 AM

Nasdaq : TWST

Twist Bioscience to Expand Oregon Lease, Supporting Future Growth

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has exercised its right of first refusal to expand the lease for its "Factory of the Future" manufacturing

RHEA-AI

neutral

04/14/21 8:00 AM

Nasdaq : TWST

Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Pure Biologics to accelerate the discovery of immuno-oncology antibody-based drugs.This press

RHEA-AI

very positive

04/12/21 8:00 AM

Nasdaq : TWST

Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software

Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will exercise its option to purchase all rights to a G-coupled protein receptor (GPCR) library and its proprietary Twist

RHEA-AI

very positive

04/07/21 10:00 PM

Nasdaq : TWST

AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests

AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation panels into

RHEA-AI

very positive

04/07/21 8:00 AM

Nasdaq : TWST

Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience's innovative antibody

RHEA-AI

positive

04/05/21 8:00 AM

Nasdaq : TWST

Twist Bioscience Earns 2021 Great Place to Work Certification(TM)

Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, is proud to be Certified(TM) by Great Place to Work(R). The prestigious award is based entirely on what current employees say about their experience

RHEA-AI

very positive

03/25/21 8:29 AM

Nasdaq : TWST

Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, Inc., a subsidiary of Kyowa Kirin Co.,

RHEA-AI

positive

03/24/21 8:00 AM

Nasdaq : TWST

Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency Use

RHEA-AI

neutral

03/22/21 8:00 AM

Nasdaq : TWST

Twist Bioscience Functional GLP-1R Antibodies Identified From Its Proprietary Synthetic DNA GPCR Libraries Demonstrate Potent Blood Glucose Control

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced positive preclinical data demonstrating that GLP-1R antibodies identified from its proprietary G-protein coupled

RHEA-AI

neutral